Lilly and Camurus have entered into a global collaboration and license agreement, granting Lilly exclusive rights to develop, manufacture, and commercialise long-acting incretin therapies using Camurus’ FluidCrystal® technology. The deal, valued at up to US$870 M, includes a US$290 M upfront payment as well as up to US$580 M in sales-based milestones. With competition building within the lucrative market, this partnership marks a significant step towards delivering innovative, long-acting treatments for obesity, diabetes, and other chronic diseases, by leveraging Camurus’ advanced drug delivery platform.